Meanwhile, the S&P BSE Sensex was up 68.80 points or 0.22% at 32,090.05.
On the BSE, 553 shares were traded on the counter so far as against the average daily volumes of 3,328 shares in the past one quarter.
The stock had hit a high of Rs 1,844 and a low of Rs 1,821.85 so far during the day.
Alkem Laboratories said that no Form 483 was issued by United States Food & Drug Administration (USFDA) after conducting an inspection at the company's Bioequivalence facility located at Taloja, Navi Mumbai from 10 July 2017 to 14 July 2017.
The stock had dropped 3.12% in four sessions to Rs 1,787.90 on 14 July 2017 from a close of Rs 1,845.65 on 10 July 2017.
Alkem Laboratories' consolidated net profit rose 58.3% to Rs 136.96 crore on 9% rise in net sales to Rs 1251.4 crore in Q4 March 2017 over Q4 March 2016.
Alkem Laboratories is a pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)